Search results for "Lymphatic"

showing 10 items of 1179 documents

Multivariate independent prognostic factors in endometrial carcinoma: A clinicopathologic study in 181 patients: 10 years experience at the Departmen…

2003

The aim of this study was to evaluate the biologic outcome of endometrial carcinomas as compared to clinical and pathologic parameters and to identify multivariate independent prognostic factors. Charts were abstracted from patients with endometrial carcinoma from 1985 to 1995. Data on clinicopathologic variables, adjuvant treatment, site of recurrence, and survival were collected. chi2 test was used to test association between variables. Kaplan-Maier method was used for survival analysis and Cox proportional hazards model for multiple regression analysis. Univariate analysis revealed that FIGO stage, tumor grade, depth of myometrial invasion, biochemical analysis of progesterone receptor s…

AdultOncologymedicine.medical_specialtyMultivariate analysisAdenocarcinomaMedical RecordsCarcinoma AdenosquamousObstetrics and gynaecologyGermanyInternal medicineDiabetes MellitusCarcinomaHumansMedicineNeoplasm InvasivenessStage (cooking)Survival analysisAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overMetaplasiaUnivariate analysisbusiness.industryProportional hazards modelObstetrics and GynecologyMiddle AgedProgesterone Receptor StatusPrognosismedicine.diseaseSurvival AnalysisEndometrial NeoplasmsOncologyLymphatic MetastasisMultivariate AnalysisFemaleNeoplasm Recurrence LocalbusinessInternational Journal of Gynecological Cancer
researchProduct

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid…

2008

Abstract Imatinib mesylate, a targeted inhibitor of BCR-ABL tyrosine kinase, is the standard of care for chronic myeloid leukemia (CML). A phase 2 trial of imatinib in late chronic-phase (CP) CML after interferon-α (IFNα) failure enrolled 532 patients, 454 with a confirmed diagnosis of CP CML. Median time from diagnosis was 34 months; median duration of imatinib treatment was 65 months. Cumulative best rates of major cytogenetic response (MCyR) and complete cytogenetic response (CCyR) were 67% and 57%, respectively. At the 5-year landmark, 184 (41%) of the 454 patients are in CCyR. At more than 6 years, 199 (44%) of the 454 patients remain on imatinib. Most responses occurred within 12 mont…

AdultOncologymedicine.medical_specialtyTime FactorsAdolescentDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classImmunologyimatinib CML interferon-alphaSalvage therapyBlastic PhaseBiochemistryPiperazinesTyrosine-kinase inhibitorhemic and lymphatic diseasesInternal medicinemedicineHumansneoplasmsSurvival rateAgedAged 80 and overSalvage Therapybusiness.industryInterferon-alphaMyeloid leukemiaImatinibCell BiologyHematologyMiddle Agedmedicine.diseaseSurgerySurvival RatePyrimidinesTreatment OutcomeImatinib mesylateBenzamidesLeukemia Myeloid Chronic-PhaseDisease ProgressionImatinib MesylatebusinessFollow-Up StudiesChronic myelogenous leukemiamedicine.drug
researchProduct

Expression Levels and Clinical-Pathological Correlations of HER2/neu in Primary and Metastatic Human Breast Cancer

2005

In this retrospective study we assessed the expression of the HER2/neu oncogene product in a series of 574 consecutive breast cancer cases, all recruited at the Maurizio Ascoli Cancer Center of Civico Hospital, in Palermo, between January 1998 and June 2003. The HER2/neu expression was evaluated using immunohistochemistry and scored from 0 to +3 as per FDA recommendations. The HER2/neu expression levels were related to the clinical-pathological features of the disease, including tumor size, nodal and menopausal status, estrogen and progesterone receptors, and hormonal or chemotherapeutic treatment. In 108 patients with a follow-up period of 3 years or more, the HER2/neu expression was also …

AdultOncologymedicine.medical_specialtyTime FactorsReceptor ErbB-2medicine.drug_classBreast NeoplasmsDisease-Free SurvivalGeneral Biochemistry Genetics and Molecular BiologyHER2/neuBreast cancerHistory and Philosophy of ScienceInternal medicineBiomarkers TumormedicineHumansNeoplasm Metastasisskin and connective tissue diseasesPathologicalIn Situ Hybridization FluorescenceAgedRetrospective StudiesbiologyOncogenebusiness.industryGeneral NeuroscienceCancerRetrospective cohort studyMiddle Agedmedicine.diseaseImmunohistochemistryGene Expression Regulation NeoplasticTreatment OutcomeEstrogenLymphatic Metastasisbiology.proteinImmunohistochemistryFemalebusinessAnnals of the New York Academy of Sciences
researchProduct

Current results on the use of imatinib mesylate in patients with relapsed philadelphia chromosome positive leukemia after allogeneic or syngeneic hem…

2003

Here, we describe a patient diagnosed with chronic myelogenous leukemia who relapsed after matched unrelated donor SCT. The patient was treated with imatinib mesylate and donor lymphocyte infusions, and achieved a complete molecular remission. Additionally, safety and efficacy of imatinib mesylate in a total of 134 patients from 8 centers who underwent allogeneic or syngeneic stem cell transplantation (SCT) and had a relapse of Philadelphia chromosome positive leukemia was reviewed. Data was compiled from abstracts accepted as oral or poster presentations at the ASH (American Society of Hematology) 2001 and EBMT (European Group for Blood and Marrow Transplantation) 2001 & 2002 meetings and …

AdultOncologymedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulationAntineoplastic AgentsHematopoietic stem cell transplantationPolymerase Chain ReactionPiperazinesRecurrenceLeukemia Myelogenous Chronic BCR-ABL Positivehemic and lymphatic diseasesInternal medicinemedicineHumansTransplantation Homologouseducationeducation.field_of_studyHematologybusiness.industryHematopoietic Stem Cell TransplantationGeneral Medicinemedicine.diseaseSurgerySyngeneic stem cell transplantationTransplantationTransplantation IsogeneicLeukemiaPyrimidinesTreatment OutcomeImatinib mesylateBenzamidesImatinib MesylateFemalebusinessChronic myelogenous leukemiaThe Keio Journal of Medicine
researchProduct

Cytoskeletal Heterogeneity of an Epithelioid Sarcoma with Expression of Vimentin, Cytokeratins, and Neurofilaments

1990

We studied an unusual sarcoma with morphologic features diagnostic of epithelioid sarcoma by conventional light microscopy, transmission electron microscopy, and immunohistochemistry. The primary tumor, which was located in the deep soft tissues of the buttock of a 32-year-old woman, and its metastases to lymph nodes, liver, and lung were available for investigation. The histomorphological and ultrastructural appearance of the primary tumor and its metastatic deposits were typical of epithelioid sarcoma. Immunohistochemistry revealed a strong and uniform reactivity for vimentin in both the primary tumor and its metastases. In contrast, a marked cytoskeletal heterogeneity became evident for …

AdultPathologymedicine.medical_specialtyLung NeoplasmsNeurofilamentEpithelioid sarcomaIntermediate FilamentsVimentinBiologyEndoplasmic ReticulumPathology and Forensic MedicinemedicineHumansVimentinIntermediate filamentCytoskeletonLiver NeoplasmsSarcomamedicine.diseaseImmunohistochemistryPrimary tumorMicroscopy ElectronLymphatic Metastasisbiology.proteinButtocksKeratinsImmunohistochemistryFemaleSurgeryLymph NodesSarcomaLymphAnatomyThe American Journal of Surgical Pathology
researchProduct

Hereditary Progressive Mucinous Histiocytosis in Women

1988

We describe three female patients in a family of two generations, who suffered from generalized and maximally pea-sized histiocytic tumors beginning in early adolescence. The disease ran a uniform and slowly progressive course and was confined to the skin. There were no signs of spontaneous tumor regression. Histologic, immunohistochemical, and ultrastructural examination revealed the histiocytic nature of the tumors. An outstanding finding was a marked production of mucinous material, predominantly in long-standing tumors. This nonlangerhansian syndrome differs from other benign normolipemic histiocytic diseases with generalized histiocytic tumors by inheritance, which is most likely autos…

AdultPathologymedicine.medical_specialtyMucous Membranebusiness.industryEarly adolescenceHistiocytesDermatologyGeneral MedicineDiseaseMiddle Agedmedicine.diseasePedigreeLymphatic diseaseHereditary progressive mucinous histiocytosisHistiocytosesFemale patientHumansImmunohistochemistryMedicineFemalebusinessLymphatic DiseasesHistiocyteArchives of Dermatology
researchProduct

Proliferating tricholemmal tumour with lymph node metastases

1989

SUMMARY A 42-year-old woman with a proliferating tricholemmal tumour (PTT) with regional lymph node metastases is reported. Histochemical studies showed evidence of tricholemmal keratinization. There was recurrence following excision and subsequently the patient developed lymph node metastases.

AdultPathologymedicine.medical_specialtyScalpSkin Neoplasmsbusiness.industryDermatologymedicine.anatomical_structureLymphatic MetastasismedicineHumansKeratinsFemaleNeoplasm Recurrence LocalbusinessLymph nodeBritish Journal of Dermatology
researchProduct

Three-dimensional sonographic diagnosis of a large cystic neck lymphangioma.

2004

Lymphangiomas are fairly well-circumscribed benign masses of lymphatic vessels or channels that vary in size, are usually greatly dilated, and are lined with normal endothelial cells. They may be classified into 3 groups: lymphangioma simplex, consisting of capillary-sized channels; cavernous lymphangiomas, consisting of dilated channels with a fibrous adventitial covering; and cystic lymphangiomas, or hygromas, composed of multiple cysts of varying sizes that are lined with endothelial cells. Mixed types may coexist within a given lesion. Although lymphangiomas can occur in any part of the body where lymphatic ducts are located, 95% of them are found in the neck, the head, or the axilla. 1…

AdultPathologymedicine.medical_specialtyUltrasonography PrenatalLesionImaging Three-DimensionalPregnancyHydrops fetalisLymphangiomamedicineHumansRadiology Nuclear Medicine and imagingCystRadiological and Ultrasound Technologybusiness.industryLymph ductAnatomymedicine.diseaseMultiple cystsbody regionsAxillaFetal Diseasesmedicine.anatomical_structureLymphatic systemHead and Neck NeoplasmsFemaleLymphangioma Cysticmedicine.symptombusinessJournal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
researchProduct

Complications of Poly Implant Prothèse breast implants: the current discussion

2013

Against the background of the current discussion about Poly Implant Prothèse (PIP, Seyne-sur-mer, France) breast implants, we want to present a case demonstrating the complications such as implant rupture, silicone dissemination and level III silicone lymphadenopathy. A 29-year-old woman with cosmetic breast augmentation with PIP implants 5 years previously showed a sensitive swelling in her right axilla and neck region. All tests to detect an infectious or lymphomatous lymphadenopathy were negative. After ultrasound and MRI, rupture of the right implant was assumed and multiple pathologically enlarged lymph nodes up to supraclavicular region were shown. An excision biopsy of one axillary l…

AdultReoperationmedicine.medical_specialtyAxillary lymph nodesBiopsyBreast ImplantsBiomedical EngineeringProsthesis DesignSilicone Gelschemistry.chemical_compoundSiliconeBiopsymedicineHumansBreast ImplantationLymphatic DiseasesBreast augmentationLymph nodeDevice Removalmedicine.diagnostic_testbusiness.industryForeign-Body ReactionGeneral MedicineProsthesis FailureSurgeryAxillaTreatment Outcomemedicine.anatomical_structurechemistryAxillaLymph Node ExcisionFemaleSurgeryLymph NodesLymphImplantbusinessExpert Review of Medical Devices
researchProduct

Does Conservative Surgery for Breast Carcinoma Still Require Axillary Lymph Node Evaluation? A Retrospective Analysis of 1156 Consecutive Women With …

2016

Abstract Background The role of axillary surgery for early breast carcinoma treated with conservative surgery and radiotherapy is currently the subject of considerable investigation. Recent studies have supported the noninferiority of avoiding axillary surgery in terms of overall survival when sentinel lymph node biopsy (SLNB) presents ≤ 2 positive lymph nodes, thus sparing the patients from complications. There are some ongoing studies investigating the possibility of omitting SLNB. Axillary study seems to be sufficiently replaced by SLNB for staging the disease. Axillary surgery maintains a therapeutic role in the presence of > 2 metastatic lymph nodes at SLNB. Patients and Methods We per…

AdultT1 tumorsCancer Researchmedicine.medical_specialtymedicine.medical_treatmentSentinel lymph nodePopulationBreast Neoplasms030230 surgeryConservative Treatment03 medical and health sciences0302 clinical medicineBreast cancerAxillary lymph node dissectionmedicineHumansMore than two metastatic axillary lymph nodeeducationLymph nodeAgedNeoplasm StagingRetrospective StudiesAged 80 and overeducation.field_of_studybusiness.industrySentinel Lymph Node BiopsyAxillary Lymph Node DissectionAxillary lymph node dissection; More than two metastatic axillary lymph nodes; Not axillary surgery staging; Sentinel lymph node biopsy; T1 tumorsMiddle Agedmedicine.diseaseSurgeryRadiation therapymedicine.anatomical_structureOncology030220 oncology & carcinogenesisLymphatic MetastasisAxillaLymph Node ExcisionNot axillary surgery stagingFemaleRadiotherapy AdjuvantLymphSentinel Lymph NodeBreast carcinomabusinessClinical breast cancer
researchProduct